Population-Based Study of Emergence and Spread of Escherichia coli Producing OXA-48-Like Carbapenemases, Israel, 2007-2023.

Publisher: National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC) Country of Publication: United States NLM ID: 9508155 Publication Model: Print Cited Medium: Internet ISSN: 1080-6059 (Electronic) Linking ISSN: 10806040 NLM ISO Abbreviation: Emerg Infect Dis Subsets: MEDLINE

Original Publication: Atlanta, GA : National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), [1995-

beta-Lactamases*/genetics ; Escherichia coli*/genetics ; Escherichia coli*/enzymology ; Escherichia coli*/isolation & purification ; Escherichia coli Infections*/epidemiology ; Escherichia coli Infections*/microbiology; Israel/epidemiology ; Humans ; Escherichia coli Proteins/genetics ; Disease Outbreaks ; Adult ; Male ; Female ; Bacterial Proteins/genetics ; Bacterial Proteins/metabolism ; History, 21st Century ; Middle Aged ; Adolescent ; Aged ; Child, Preschool ; Child ; Microbial Sensitivity Tests ; Cross Infection/epidemiology ; Cross Infection/microbiology ; Young Adult

Escherichia coli producing OXA-48-like carbapenemases (OXA-EC) is considered a high-risk pathogen spread primarily in the community in low- and middle-income countries and nosocomially in high-income countries. We investigated the emergence and spread of OXA-EC in Israel, a high-income country with strong carbapenemase-directed infection control in healthcare institutions, by conducting a population-based study using data and isolates from the national surveillance system. A total of 3,510 incident cases of OXA-EC occurred during 2007-2023. During 2016-2023, annual cases rose from 41 to 1,524 and nonnosocomial cases rose from 39% to 57%. Sixty-three sequenced isolates belonged to 20 sequence types (STs) and had 3 bla OXA alleles (bla OXA-244 , bla OXA-48 , and bla OXA-181 ); 71% were chromosomally encoded, and 29% were plasmid-encoded. Nosocomially and non-nosocomially acquired isolates belonged to the same STs and alleles. Most outbreaks involved multiple STs and could only partially be explained by plasmid dissemination. Measures for confronting OXA-EC might need reconsideration.

Anal Bioanal Chem. 2022 Oct;414(24):7179-7189. (PMID: 35962141)
J Clin Microbiol. 2020 Apr 23;58(5):. (PMID: 32161093)
Emerg Infect Dis. 2021 Apr;27(4):1206-1210. (PMID: 33755001)
JAMA. 2008 Dec 24;300(24):2911-3. (PMID: 19109119)
Infect Dis Clin North Am. 2020 Dec;34(4):709-722. (PMID: 33011046)
Virulence. 2017 May 19;8(4):460-469. (PMID: 27593176)
J Antimicrob Chemother. 2022 Sep 30;77(10):2763-2771. (PMID: 36179278)
Antimicrob Agents Chemother. 2017 Aug 24;61(9):. (PMID: 28674064)
Am J Infect Control. 2023 Jan;51(1):70-77. (PMID: 35909003)
Clin Microbiol Rev. 2019 Nov 13;33(1):. (PMID: 31722889)
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0021622. (PMID: 35856662)
J Antimicrob Chemother. 2011 Mar;66(3):672-3. (PMID: 21177669)
J Clin Microbiol. 2023 Oct 24;61(10):e0034723. (PMID: 37787542)
J Antimicrob Chemother. 2011 Dec;66(12):2763-6. (PMID: 22191089)
Nat Commun. 2022 Jun 1;13(1):3052. (PMID: 35650193)
J Clin Microbiol. 2013 Sep;51(9):2926-30. (PMID: 23804390)
J Antimicrob Chemother. 2024 Feb 1;79(2):349-353. (PMID: 38101944)
Antimicrob Agents Chemother. 2004 Jan;48(1):15-22. (PMID: 14693513)
J Clin Microbiol. 2021 Nov 18;59(12):e0021321. (PMID: 34550809)
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):383-393. (PMID: 30488368)
Eur J Clin Microbiol Infect Dis. 2018 Apr;37(4):587-604. (PMID: 28990132)
Clin Infect Dis. 2011 Apr 1;52(7):848-55. (PMID: 21317398)
Infect Control Hosp Epidemiol. 2018 Jan;39(1):85-89. (PMID: 29241475)
Int J Antimicrob Agents. 2017 Aug;50(2):127-134. (PMID: 28647532)
Clin Microbiol Infect. 2020 Apr;26(4):401-403. (PMID: 31899334)
Diagn Microbiol Infect Dis. 2018 Feb;90(2):77-80. (PMID: 29150373)
Infect Control Hosp Epidemiol. 2007 Aug;28(8):945-50. (PMID: 17620242)

Investigator: T Brosh-Nissimov; N Sorek; HB Zvi; R Chervet; NH Wolf; O Nisimov; B Rubinovitch; T Boumard; E Gofaize; B Mendelson; A Paz; M Hershman-Sarafov; M Feldman; O Salah; R Najjar-Debbiny; I Avraham; M Strauss; B Chazan; T Bendahan; A Favor; I Gross; K Harpaz; J Hen; M Ottolenghi; E Radvogin; N Reichman; N Ronen; N Shilo; S Zahran; Y Oster; R Fedorowsky; R Yerushalmi; T Gottesman; OB Natan; M Ganayem; A Vaknin; R Cohen; R Bardenstein; P Ciobotaro; C Uliel; M Afraimov; D Atiya; J Lellouche; BS Kloyzner; H Arielly; O Benisty; P Shitrit; D Schwartz; A Nutman; V Schechner; W Aboalhega; T Alon; I Firan; M Hamo; E Lomansov; S Mendelsohn; D Pollak; MS Cohen; J Tarabeia; M Mor; S Rozenfeld; SA Ghosh; B Ezagui; M Assous; S Benenson; O Bondar; L Goldshtein; D Nestor; JA Hanna; M Berbi; O Henig; A Medovy; S Stepansky; M Azrad; H Zayyad; D Ben-David; Y Cohen
Keywords: Escherichia coli; Israel; antimicrobial resistance; bacteria; bacterial infections; carbapenemase; food safety; molecular epidemiology

EC 3.5.2.6 (beta-Lactamases)
EC 3.5.2.6 (carbapenemase)
0 (Escherichia coli Proteins)
EC 3.5.2.6 (beta-lactamase OXA-48, E coli)
0 (Bacterial Proteins)

Date Created: 20241223 Date Completed: 20241223 Latest Revision: 20250112

20250112

PMC11682801

10.3201/eid3101.240722

39714269